Future in vivo studies are necessary to evaluate the pharmacokinetics, blood-brain barrier permeability, and comparative therapeutic efficacy of type I and type II PDGFRA TKI inhibitors in glioblastoma models with PDGFRA alterations. The gene discussed is PDGFRA; the disease is glioblastoma.